FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2103708944> ?p ?o ?g. }

• W2103708944 endingPage "548" @default.
• W2103708944 startingPage "541" @default.
• W2103708944 abstract "It has been shown that T lymphocytes and monocytes/macrophages, producing pro-inflammatory cytokines, play a pivotal role in the pathophysiology of rheumatoid arthritis (RA). In recent placebo-controlled double-blind randomized studies, chimeric (human/mouse) tumour necrosis factor-alpha (TNFalpha) antibodies (cA2) proved to be very effective in improving clinical disease activity and reducing inflammatory parameters in RA.To investigate whether anti-TNFalpha therapy influences the in vitro intracellular cytokine production in peripheral blood monocytes and T lymphocytes of RA patients after one single (24 h) and multiple intravenous infusions (6 months).An intracellular flow cytometric technique was applied to measure interleukin 1beta (IL-1beta), IL-6, TNFalpha, IL-10 and IL-12 in monocytes and IL-2, IL-4 and interferon-gamma in T lymphocytes of 15 patients, before, after 24 h and after 6 months of therapy with monoclonal chimeric anti-TNFalpha antibodies (3 mg/kg, bimonthly i.v.). All patients were on stable therapy with methotrexate (15-20 mg/week i.m.). Cytokine content in monocytes was measured directly after blood sampling (basal levels), after 8 h of culture (spontaneous production) and after 8 h of stimulation with lipopolysaccharides (LPS-stimulated production).Basal levels and production (after 8 h) of IL-1beta, IL-6 and TNFalpha were significantly decreased 24 h after the first administration of anti-TNFalpha (for IL-1beta P < 0.01; for IL-6 P < 0.01; for TNF P < 0.003) and after 6 months of therapy (for IL-1beta P < 0.02; for IL-6 P < 0.03; for TNFalpha P < 0.001). For IL-12, basal levels were significantly decreased 24 h and 6 months after the start of therapy with anti-TNFalpha antibodies (P=0.0001; P=0.003, respectively). In contrast, IL-10 production increased significantly after 24 h and after 6 months (P=0.02; P=0.01). The T(H2)/T(H1) cytokine ratio in CD4+ T cells was significantly increased after 24 h and after 6 months of anti-TNFalpha therapy (P=0.003; P=0.0007).Anti-TNFalpha therapy might down-regulate the monocytic capacity to produce pro-inflammatory cytokines and induces a shift to a more pronounced anti-inflammatory T(H2) cytokine production." @default.
• W2103708944 created "2016-06-24" @default.
• W2103708944 creator A5003652734 @default.
• W2103708944 creator A5012298568 @default.
• W2103708944 creator A5037598384 @default.
• W2103708944 creator A5041256007 @default.
• W2103708944 creator A5079609914 @default.
• W2103708944 date "2003-02-28" @default.
• W2103708944 modified "2023-10-01" @default.
• W2103708944 title "Influence of therapy with chimeric monoclonal tumour necrosis factor-alpha antibodies on intracellular cytokine profiles of T lymphocytes and monocytes in rheumatoid arthritis patients" @default.
• W2103708944 cites W1527717973 @default.
• W2103708944 cites W1528765374 @default.
• W2103708944 cites W1892298186 @default.
• W2103708944 cites W1985680749 @default.
• W2103708944 cites W1985763670 @default.
• W2103708944 cites W1996472975 @default.
• W2103708944 cites W2007088223 @default.
• W2103708944 cites W2020400759 @default.
• W2103708944 cites W2024262400 @default.
• W2103708944 cites W2031172875 @default.
• W2103708944 cites W2033299724 @default.
• W2103708944 cites W2035538567 @default.
• W2103708944 cites W2043287930 @default.
• W2103708944 cites W2043743844 @default.
• W2103708944 cites W2048488222 @default.
• W2103708944 cites W2055669282 @default.
• W2103708944 cites W2057631395 @default.
• W2103708944 cites W2059490409 @default.
• W2103708944 cites W2062563784 @default.
• W2103708944 cites W2065012515 @default.
• W2103708944 cites W2066246367 @default.
• W2103708944 cites W2072738451 @default.
• W2103708944 cites W2084030755 @default.
• W2103708944 cites W2085853581 @default.
• W2103708944 cites W2091651459 @default.
• W2103708944 cites W2101951838 @default.
• W2103708944 cites W2109830819 @default.
• W2103708944 cites W2111282166 @default.
• W2103708944 cites W2118110579 @default.
• W2103708944 cites W2133602875 @default.
• W2103708944 cites W2139162201 @default.
• W2103708944 cites W2140611998 @default.
• W2103708944 cites W2141931937 @default.
• W2103708944 cites W2142273705 @default.
• W2103708944 cites W2143939606 @default.
• W2103708944 cites W2152348310 @default.
• W2103708944 cites W2191654227 @default.
• W2103708944 cites W2319957449 @default.
• W2103708944 cites W2328587823 @default.
• W2103708944 cites W2340084730 @default.
• W2103708944 cites W2395262053 @default.
• W2103708944 cites W4752647 @default.
• W2103708944 cites W46650105 @default.
• W2103708944 doi "https://doi.org/10.1093/rheumatology/keg171" @default.
• W2103708944 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12649401" @default.
• W2103708944 hasPublicationYear "2003" @default.
• W2103708944 type Work @default.
• W2103708944 sameAs 2103708944 @default.
• W2103708944 citedByCount "43" @default.
• W2103708944 countsByYear W21037089442012 @default.
• W2103708944 countsByYear W21037089442014 @default.
• W2103708944 countsByYear W21037089442015 @default.
• W2103708944 countsByYear W21037089442017 @default.
• W2103708944 countsByYear W21037089442018 @default.
• W2103708944 countsByYear W21037089442019 @default.
• W2103708944 countsByYear W21037089442020 @default.
• W2103708944 countsByYear W21037089442021 @default.
• W2103708944 countsByYear W21037089442022 @default.
• W2103708944 countsByYear W21037089442023 @default.
• W2103708944 crossrefType "journal-article" @default.
• W2103708944 hasAuthorship W2103708944A5003652734 @default.
• W2103708944 hasAuthorship W2103708944A5012298568 @default.
• W2103708944 hasAuthorship W2103708944A5037598384 @default.
• W2103708944 hasAuthorship W2103708944A5041256007 @default.
• W2103708944 hasAuthorship W2103708944A5079609914 @default.
• W2103708944 hasConcept C11988809 @default.
• W2103708944 hasConcept C126322002 @default.
• W2103708944 hasConcept C159654299 @default.
• W2103708944 hasConcept C17991360 @default.
• W2103708944 hasConcept C203014093 @default.
• W2103708944 hasConcept C2777575956 @default.
• W2103708944 hasConcept C2778690821 @default.
• W2103708944 hasConcept C2781184567 @default.
• W2103708944 hasConcept C542903549 @default.
• W2103708944 hasConcept C71924100 @default.
• W2103708944 hasConceptScore W2103708944C11988809 @default.
• W2103708944 hasConceptScore W2103708944C126322002 @default.
• W2103708944 hasConceptScore W2103708944C159654299 @default.
• W2103708944 hasConceptScore W2103708944C17991360 @default.
• W2103708944 hasConceptScore W2103708944C203014093 @default.
• W2103708944 hasConceptScore W2103708944C2777575956 @default.
• W2103708944 hasConceptScore W2103708944C2778690821 @default.
• W2103708944 hasConceptScore W2103708944C2781184567 @default.
• W2103708944 hasConceptScore W2103708944C542903549 @default.
• W2103708944 hasConceptScore W2103708944C71924100 @default.
• W2103708944 hasIssue "4" @default.
• W2103708944 hasLocation W21037089441 @default.
• W2103708944 hasLocation W21037089442 @default.

• next